Our data agree with previously reported gnetin C activity on AKT/mTOR signaling in leukemia cells, in which gnetin C’s antitumor effects are demonstrated in cancer cell lines, patient samples, and in vivo through AKT/mTOR and ERK1/2 pathways. Here, MTOR is linked to leukemia.